We are a late-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for refractive and retina disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting significant unmet needs.
Location: United States, Michigan, Farmington Hills
Employees: 11-50
Total raised: $20M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Michigan A... | miangelfun... |
| - | BELLE Impa... | bellefunds... |
| - | ID Venture... | idventures... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.06.2021 | - | $15M | - |
| 22.07.2019 | - | $5M | - |
Mentions in press and media 15
| Date | Title | Description |
| 28.10.2024 | Ocuphire Pharma Acquires Opus Genetics | Ocuphire Pharma (Nasdaq: OCUP), a Farmington Hills, MI-based clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with retinal and refractive eye disorders, ac... |
| 22.10.2024 | Ocuphire Pharma Announces Acquisition of Opus Genetics | Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early ons... |
| 30.09.2024 | Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology | FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of ... |
| 13.08.2024 | Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update | VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2... |
| 08.08.2024 | Ocuphire Pharma to Present at Two Investor Conferences in August | FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of p... |
| 10.07.2024 | Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July | CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIR... |
| 10.05.2024 | Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update | FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal ... |
| 08.03.2024 | Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update | - |
| 27.11.2023 | Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of r... |
| 27.06.2023 | Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference | /EIN News/ -- FARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the ... |
Show more